ロード中...
Multicenter Phase I Dose Escalation Study of Hypofractionated Stereotactic Radiotherapy with Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma
PURPOSE: It has been reported previously that the combination of bevacizumab with hypofractionated stereotactic re-irradiation (HFSR) with 30Gy (6GyX5 fractions) was safe and efficacious in recurrent glioblastomas and high-grade gliomas (HGG). Because most recurrences are local, developing intensifi...
保存先:
| 出版年: | Int J Radiat Oncol Biol Phys |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5654655/ https://ncbi.nlm.nih.gov/pubmed/28870792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2017.06.2466 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|